Advanced ovarian carcinoma. Factors influencing survival

Baruch Klein, Geoffrey Falkson, C. F. Smit

Research output: Contribution to journalArticlepeer-review


One hundred ten patients with advanced ovarian carcinoma (Stages IIIA, IIIB, and IV) were evaluated for survival. They received as first treatment one of the following regimens: melphalan (L‐PAM) (41 patients), cyclophosphamide plus methotrexate plus 5‐fluorouracil (CMF) (16 patients), cyclophosphamide plus doxorubicin plus 5‐fluorouracil (CAF) (17 patients), cyclophosphamide plus doxorubicin plus hexamethylmelamine plus cisplatin (CHAD) (13 patients, thiotepa plus methotrexate (TM) with fixed rotation with CAF (TM/CAF) (17 patients), and 6 patients received other chemotherapy as first treatment. There was no significant difference in survival time with the various treatment arms despite differences in response rates. Patients with Stage IIIA had significantly longer survival than those with Stages IIIB and IV (P < 0.01). Patients with good performance status (PS 0) had significantly better survival than those with poor performance status (PS 3–4) (P < 0.02). At this time the improved response rates on combination chemotherapy has not given improved survival rates, and disease stage and performance status remain of prime importance in survival prediction.

Original languageEnglish
Pages (from-to)1829-1834
Number of pages6
Issue number8
StatePublished - 15 Apr 1985
Externally publishedYes


Dive into the research topics of 'Advanced ovarian carcinoma. Factors influencing survival'. Together they form a unique fingerprint.

Cite this